ANTY EXPO: Elux Showcases Open-System CYBEROVER P1, In-House E-Liquid Brand Yet to Debut in Malaysia

Events by 2FIRSTS
Sep.06.2024
ANTY EXPO: Elux Showcases Open-System CYBEROVER P1, In-House E-Liquid Brand Yet to Debut in Malaysia
ANTY EXPO opens in Malaysia showcasing e-cigarette innovations including CYBEROVER and CYBEROVER P1 by Elux.

On September 6, 2024, the Asia International New Tobacco Industry Expo (ANTY EXPO) officially opened at the Malaysia International Exhibition and Convention Centre (MIECC). As the official media partner of ANTY EXPO, the 2Firsts team has arrived at the exhibition site and set up a special interview room (booth number: H30) to provide industry professionals with first-hand market insights and trend analysis. Industry insiders are welcome to come and exchange industry news. According to 2Firsts, the well-known e-cigarette brand Elux is showcasing CYBEROVER and the open oil-infused product CYBEROVER P1 at the event. It is worth noting that CYBEROVER has already been launched in markets such as the United States this year.

 

ANTY EXPO: Elux Showcases Open-System CYBEROVER P1, In-House E-Liquid Brand Yet to Debut in Malaysia
CYBEROVER | Image source: 2Firsts

 

ANTY EXPO: Elux Showcases Open-System CYBEROVER P1, In-House E-Liquid Brand Yet to Debut in Malaysia
CYBEROVER Page 1 | Image source: 2Firsts

 

During the event, CYBEROVER P1 can be used with e-liquid. In addition, ELUX also showcased its own brand of e-liquid, but the booth staff stated that their e-liquid is not yet available on the market in Malaysia.

 

According to reports, the CYBEROVER P1 can accommodate three different pods (0.4Ω, 0.6Ω, 0.8Ω), while the refillable version CYBEROVER is equipped with dual heating coils.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
During the FDA PMTA roundtable session on “Studies of Adult Benefit,” officials said flavored ENDS must demonstrate “added benefit” over tobacco-flavored products under the APPH standard, including sustained complete switching evidence. Small manufacturers questioned switching benchmarks, study duration, and bridging expectations.
Feb.11
3,200 suspected "drug-laced cigarettes" seized in Johor Bahru, case value estimated at US$242,500
3,200 suspected "drug-laced cigarettes" seized in Johor Bahru, case value estimated at US$242,500
Malaysian police seized 3,200 suspicious e-pods with ketamine liquid, arresting two men in Johor Bahru's drug distribution bust.
Feb.04 by 2FIRSTS.ai
Brazil’s Teen E-Cigarette Experimentation Rate Rises to 29.6% Over Five Years
Brazil’s Teen E-Cigarette Experimentation Rate Rises to 29.6% Over Five Years
Brazil’s National School Health Survey (PeNSE) 2024 found that e-cigarette experimentation among students aged 13 to 17 rose from 16.8% in 2019 to 29.6% in 2024, while use in the previous 30 days increased from 8.6% to 26.3%. Over the same period, conventional cigarette experimentation fell from 22.6% to 18.5%, and hookah use declined from 26.9% to 16.4%.
Mar.26 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
South Dakota Legislature Approves Two Nicotine Licensing Bills Pending Governor’s Decision
South Dakota Legislature Approves Two Nicotine Licensing Bills Pending Governor’s Decision
The South Dakota Legislature gave final approval on Tuesday to two proposals requiring state licenses for businesses that sell nicotine products. Under the bills, wholesalers, distributors and retailers of nicotine products in the state would need to be licensed by the government.
Mar.12 by 2FIRSTS.ai
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
A cross-sectional analysis based on the US NHANES 2021–2023 cycle, including 6,262 participants aged over 12, found that compared with people who neither smoke nor vape, those who smoke and/or use e-cigarettes had a higher prevalence of elevated blood pressure and hypertension. After full adjustment, smoking/vaping was associated with elevated blood pressure (aOR 1.34) and hypertension (aOR 1.46), and with a 1.05 mmHg higher diastolic blood pressure.
Feb.09 by 2FIRSTS.ai